Specifically, they are approved in patients who have a BMI 30 kg/m 2 or who have a BMI 27 kg/m 2 and an obesity-related health condition (eg, diabetes, hypertension, or dyslipidemia)
Cost and accessibility have been cited as the main barriers to their use, although there have been other issues moderating their uptake
They result from a combination of factors such as decreased collagen and elastin production, loss of hydration, and cumulative damage from environmental factors like UV exposure
Think Greek yogurt with banana, chicken and rice soup, a tuna snack plate, cottage cheese with crackers, or scrambled egg with toast
Options like ipamorelin, semaglutide, or tirzepatide can all support fat loss in different ways